U.S. markets closed

Zymergen Inc. (ZY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.65+0.22 (+0.50%)
At close: 4:00PM EDT
44.65 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close44.43
Open44.76
Bid44.53 x 800
Ask44.66 x 1200
Day's Range43.61 - 45.39
52 Week Range25.75 - 52.00
Volume295,491
Avg. Volume575,675
Market Cap4.48B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 24, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zymergen to Present at Goldman Sachs Annual Global Healthcare Conference
    GlobeNewswire

    Zymergen to Present at Goldman Sachs Annual Global Healthcare Conference

    EMERYVILLE, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Biofacturing leader Zymergen today announced the company will be participating in the upcoming Goldman Sachs Annual Global Healthcare Virtual Conference. Zymergen’s management is scheduled to present on Wednesday, June 9th at 5:30 p.m. Eastern Time/2:30 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.zymergen.com/. About

  • Zymergen Reports Preliminary First Quarter 2021 Financial Results
    GlobeNewswire

    Zymergen Reports Preliminary First Quarter 2021 Financial Results

    EMERYVILLE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen”), one of the world’s leading biofacturing companies, today reported preliminary financial results for the first quarter ended March 31, 2021. “I am so proud of our team for their continued execution across our organization,” says Josh Hoffman, Zymergen CEO. “With biofacturing, we are committed to transforming what is possible by partnering with nature to make better products in a better way. I am confident that we are well positioned to execute on our strategy to develop and sell superior products across multiple markets, this year and beyond.” Recent Highlights Completed initial public offering in April 2021, raising $575 million in gross proceedsStrengthened leadership by adding Aindrea Campbell as Chief Manufacturing Officer, a seasoned industry veteran who will be instrumental in the scaling of Zymergen’s production capabilities First Quarter 2021 Financial Results Total revenue was $3.7 million dollars for the three months ended March 31, 2021, all relating to R&D services agreements and Collaboration revenue. This represents a 26% increase over the same quarter in 2020, and was primarily driven by the impact of new and acquired contracts. Total operating expenses for the first quarter of 2021 were $87.1 million dollars, a 32.8% increase from $65.6 million dollars in the first quarter of 2020. The increase was driven by an increase in R&D activities to develop Hyaline production processes, as well as the additional costs associated with becoming a public company. Net loss in the first quarter of 2021 was $84.6 million dollars. Cash and cash equivalents were $121.0 million as of March 31, 2021. Subsequent to quarter end, Zymergen completed its initial public offering in April 2021 raising approximately $530 million in net proceeds. Webcast Information Zymergen will host a conference call to discuss the first quarter 2021 financial results after market close on Monday, May 24, 2021 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investors.zymergen.com/. The webcast will be archived and available for replay for at least 90 days after the event. About Zymergen Zymergen is a biofacturing company using biology to reimagine the world. Zymergen partners with nature to design, develop and manufacture bio-based breakthrough products that deliver value to customers in a broad range of industries. A unique combination of biology, chemistry, software and automation enables the company to design and create new materials. Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on the Company’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding our timing and ability to execute on our strategy to develop and sell superior products across multiple markets, this year and beyond. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s prospectus dated April 23, 2021 filed with the SEC pursuant to Rule 424 under the Securities Act of 1933, and other documents the Company subsequently files with the SEC from time to time, including the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor ContactNiraj Javeriinvestors@zymergen.com Media ContactMike Dulinmdulin@zymergen.com502-777-2029 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share and per share amounts)(unaudited) Three Months Ended March 31, 2021 2020Revenue $3,735 $2,954 Operating expenses: Cost of service revenue 21,130 24,576 Research and development 39,811 21,802 Sales and marketing 6,872 5,541 General and administrative 19,331 13,693 Total operating expenses 87,144 65,612 Loss from operations (83,409) (62,658) Other income (expense): Interest income 43 377 Interest and other expense (1,211) (3,166) Total other expense (1,168) (2,789) Loss before income taxes (84,577) (65,447) (Provision for) benefit from income taxes (8) 107 Net loss $(84,585) $(65,340) Net loss per share attributable to common stockholders, basic $(6.51) $(5.77) Net loss per share attributable to common stockholders, diluted $(6.51) $(5.77) Weighted-average shares used in computing net loss per share to common stockholders, basic 12,996,344 11,322,626 Weighted-average shares used in computing net loss per share to common stockholders, diluted 13,340,457 11,322,626 CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)(unaudited) As of March 31,2021 As of December 31,2020ASSETS Current assets: Cash and cash equivalents $121,035 $210,205 Accounts receivable, billed and unbilled 4,116 4,175 Inventory 5,683 4,969 Other current assets 8,896 9,225 Total current assets 139,730 228,574 Property and equipment, net 55,462 48,718 Goodwill 11,604 11,604 Intangible assets, net 4,443 4,790 Other assets 15,993 11,235 Total assets $227,232 $304,921 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable, accrued and other liabilities $37,520 $38,985 Short-term debt, net — 79,331 Other current liabilities 2,790 3,142 Total current liabilities 40,310 121,458 Long-term debt, net 79,615 — Warrant liabilities 11,952 14,231 Other long-term liabilities 15,490 12,170 Total liabilities 147,367 147,859 Convertible preferred stock 900,798 900,798 Total stockholders' deficit (820,933) (743,736) Total liabilities and redeemable convertible preferred stock and stockholders' deficit $227,232 $304,921

  • Zymergen to Present at UBS Global Healthcare Virtual Conference
    GlobeNewswire

    Zymergen to Present at UBS Global Healthcare Virtual Conference

    EMERYVILLE, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Biofacturing leader Zymergen today announced the company will be participating in the upcoming UBS Global Healthcare Virtual Conference. Zymergen’s management is scheduled to present on Wednesday, May 26th at 3:00 p.m. Eastern Time/12:00 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.zymergen.com/. About Zymergen Zymergen is a biofacturing company using biology to reimagine the world. Zymergen partners with nature to design, develop and manufacture bio-based breakthrough products that deliver value to customers in a broad range of industries. A unique combination of biology, chemistry, software and automation enables the company to design and create new materials. Investor ContactNiraj Javeriinvestors@zymergen.com Media ContactMike Dulinmdulin@zymergen.com502-777-2029